Assessing the value of humanin in predicting acute kidney injury
Clinical Value of Plasma Humanin in Acute Kidney Injury
This study is testing if measuring humanin levels can help doctors predict acute kidney injury in adults.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Guangdong Provincial People's Hospital Academic / other |
| Locations | 1 site (Guangdong, Guangzhou) |
| Trial ID | NCT06105229 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the clinical significance of humanin as a potential biomarker for acute kidney injury (AKI). Researchers will compare humanin levels in individuals diagnosed with AKI to those in healthy controls to determine its predictive value. Given the high incidence and mortality associated with AKI, identifying a reliable biomarker could enhance early diagnosis and treatment strategies. The study will involve adult participants aged 18 and older, with a focus on gathering comprehensive baseline medical data.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who have been diagnosed with acute kidney injury according to KDIGO guidelines.
Not a fit: Patients under 18 years of age or those with incomplete baseline medical records may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to the development of a new, more sensitive biomarker for early detection of acute kidney injury.
How similar studies have performed: While the approach of using humanin as a biomarker is novel, previous studies have shown promise in exploring biological markers for AKI, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients ≥ 18 years of age, male or female； * Patients with AKI: Patients with acute kidney injury who meet the definition of KDIGO guidelines； * Control group: from healthy physical examination population, physical examination blood routine, urine routine, liver function, kidney function, glycated hemoglobin and other indicators are normal； * The patient's baseline medical record data is complete, including liver and kidney function, urine protein level, blood creatinine value, etc； * Consent to enrollment and sign informed consent； Exclusion Criteria: * Age\< 18 years； * Baseline data were missing
Where this trial is running
Guangdong, Guangzhou
- Guangdong Provincial People's Hospital — Guangdong, Guangzhou, China (Recruiting)
Study contacts
- Study coordinator: zhilian li, doctor
- Email: lizhilian@gdph.org.cn
- Phone: 13580560903
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.